Athena Countouriotis and her former colleagues at Turning Point Therapeutics have in-licensed their first oncology asset at their next venture, Avenzo Therapeutics, which is on the hunt for more deals and financing later this year, she told Endpoints News. The San Diego startup, which has raised about $200 million so far, in-licensed a Phase I-stage … Continue reading Ex-Turning Point leaders license first oncology assets for new startup Avenzo